UBS Maintains Neutral on Amedisys, Raises Price Target to $154

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $144 to $154.

Benzinga · 11/07/2019 12:31

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $144 to $154.